Dr. Kass on Optimal Treatment Sequencing in HER2-Positive Breast Cancer

Fred C. Kass, MD, oncology/hematology, internal medicine, Cancer Center of Santa Barbara, discusses challenges associated with optimal treatment sequencing for patients with HER2-positive breast cancer.

The field of HER2-positive breast cancer is one which oncologists are gratified by the amount of treatments available to patients, Kass explains. There has been great success with adjuvant treatments, as well as personalized medicine.

However, the variation of treatments can be a drawback, as there is uncertainty on when and how to use all of the therapies. Therefore, Kass says, oncologists have not yet determined optimal treatment sequencing for HER2-positive breast cancer.